FOR IMMEDIATE RELEASE PRESS RELEASE July 7, 2008 ANGIOTECH TO ESTABLISH SEPARATE OPERATING AND ROYALTY BUSINESSES ARES MANAGEMENT AND NEW LEAF VENTURE PARTNERS COMMIT TO PURCHASE CONVERTIBLE NOTES IN NEW SUBSIDIARY OF $200 TO $300 MILLION TRANSACTION PROCEEDS TO BE USED TO REDUCE ANGIOTECH DEBT VANCOUVER, BC, July 7, 2008 – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced that Angiotech’s Board of Directors has authorized a transaction to create a new subsidiary, Angiotech Pharmaceutical Interventions, Inc. (“API”). Angiotech will contribute to API certain business assets and intellectual property, which include primarily business assets of Angiotech other than the intellectual property and royalty revenue related to the TAXUS® coronary stent system. The Company has entered into a note purchase agreement with Ares Management and New Leaf Venture Partners, under which the investors will purchase between $200 and $300 million, at the Company’s option, of convertible notes issued by API that will be convertible into a significant minority equity interest in API. Angiotech and its shareholders will benefit from the future performance of API based on retaining a significant continuing equity interest in the newly formed subsidiary. The net proceeds from the issuance of the convertible notes will be used to reduce Angiotech’s existing debt, pursuant to tender offers announced and commenced concurrent with this announcement. The transaction is subject to approval of the Company’s shareholders and other customary closing conditions. Read the full release

send this to a friend unsubscrive © LifeSciences British Columbia. All rights reserved.

Suite 900 - 1188 West Georgia St. Vancouver, BC V6E 4A2